SEC EDGAR · Financial report
TDG: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-27. Read the company report for its disclosures.
Follow TDG- Became public
- Aug 4, 2026, 4:04 PM EDT
- Event / period date
- Jun 27, 2026
- Collected
- Nov 9, 2026, 12:47 PM EST
Why this is connected
This filing identifies TransDigm Group INC as the issuer of the security. The company's SEC identifier connects it to TDG.
Source evidence
Read the source excerpt or record
tdg-20260627 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 27, 2026 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-32833 TransDigm Group Incorporated (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 41-2101738 (I.R.S. Employer Identification No.) 1350 Euclid Avenue, Suite 1600, Cleveland, Ohio 44115 (Address of principal executive offices) (Zip Code) ( 216 ) 706-2960 (Registrant’s telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report.) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, accelerated filer, non-accelerated filer, smaller reporting company or emerging growth company. See the definitions of “large accelerated fi
Price change after we could observe it
+1.59% TDG
Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in TDG
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Sep 9, 2026$100K–$250K
Rep. April McClain Delaney (D-MD-6)
$100K–$250K · Traded Aug 25, 2026 · disclosed Sep 9, 2026 · Dependent
Committee overlap: Science - Aug 3, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Jul 28, 2026 · disclosed Aug 3, 2026 · Dependent
Committee overlap: ScienceTraded 7 days before earnings - Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
- Jun 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded May 22, 2026 · disclosed Jun 5, 2026 · Dependent
Committee overlap: Science - Jun 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded May 21, 2026 · disclosed Jun 5, 2026 · Dependent
Committee overlap: Science - Jun 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded May 13, 2026 · disclosed Jun 5, 2026 · Dependent
Committee overlap: Science - Jun 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded May 8, 2026 · disclosed Jun 5, 2026 · Dependent
Committee overlap: Science - Jun 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded May 7, 2026 · disclosed Jun 5, 2026 · Dependent
Committee overlap: Science
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.